Textbook of Pharmaceutical Medicine

Detalles Bibliográficos
Autor principal: Griffin, John
Formato: Electrónico eBook
Idioma:Inglés
Publicado: Newark : Blackwell Publishing Ltd., 2002.
Colección:New York Academy of Sciences Ser.
Temas:
Electronic books.
Acceso en línea:Texto completo
Tabla de Contenidos:
  • Intro
  • Contents
  • Contributors
  • Preface
  • Acknowledgements
  • The editors
  • Part I: Research and development
  • 1: Discovery of new medicines
  • 1.1 Introduction
  • 1.2 Historical aspects
  • 1.2.1 Early discoveries
  • 1.3 Impact of new technology on drug discovery
  • 1.3.1 Receptor subtypes
  • 1.3.2 Genomics
  • 1.3.3 Pharmacogenomics
  • 1.3.4 Proteomics
  • 1.3.5 Bioinformatics and data mining technologies
  • 1.3.6 Combinatorial chemistry and high-throughput screening
  • 1.3.6.1 Combinatorial synthesis
  • 1.3.6.2 Library design
  • 1.3.7 Structure-based drug design
  • 1.3.8 Virtual screening
  • 1.3.9 NMR, x ray and mass spectroscopic techniques
  • 1.3.10 Pharmacokinetics
  • 1.4 Examples of drug discovery
  • 1.4.1 Receptor ligands (agonists and antagonists)
  • 1.4.1.1 Early examples
  • 1.4.1.2 Selective oestrogen receptor modulators (oestrogen antagonists and aromatase inhibitors)
  • 1.4.1.3 LHRH agonists and antagonists
  • 1.4.1.4 Somatostatin agonists and antagonists
  • 1.4.1.5 Angiotensin agonists and antagonists (peptides and non-peptides)
  • 1.4.1.6 Bombesin/neuromedin agonists and antagonists
  • 1.4.1.7 Bradykinin agonists and antagonists
  • 1.4.1.8 Cholecystokinin agonists and antagonists
  • 1.4.1.9 Endothelin antagonists
  • 1.5 Enzyme inhibitors
  • 1.5.1 Converting enzyme inhibitors
  • 1.5.2 Aspartyl protease (renin and HIV protease) inhibitors
  • 1.5.2.1 Renin inhibitors
  • 1.5.2.2 HIV protease inhibitors
  • 1.5.3 Thrombin inhibitors (serine protease)
  • 1.5.4 Ras protein farnesyltransferase inhibitors
  • 1.5.5 Protein kinase inhibitors
  • 1.6 Protein-protein interaction inhibitors
  • 1.6.1 a4ß1 and a5ß1 antagonists
  • 1.7 Summary
  • References
  • 2: Pharmaceutical development
  • 2.1 Introduction
  • 2.2 Preformulation
  • 2.2.1 Structure determination
  • 2.2.2 Analytical development
  • 2.2.3 Salt form
  • 2.2.4 Chemical stability
  • 2.2.5 Physicochemical properties
  • 2.2.6 Chiral properties
  • 2.2.7 Biopharmaceutical properties
  • 2.2.8 Physical properties of the solid drug
  • 2.2.9 Excipient compatibility
  • 2.3 Formulation
  • 2.3.1 Liquid formulations
  • 2.3.2 Semi-solid formulations
  • 2.3.3 Solid formulations
  • 2.3.4 Contemporary formulationsa
  • 2.3.5 Packaging
  • 2.3.6 Stability testing
  • 2.3.7 Scale-up and manufacture
  • 2.3.8 Bioequivalence
  • 2.4 Clinical trial supplies
  • 2.4.1 Blinding
  • 2.4.2 Labelling of clinical trial materials
  • 2.4.3 Quality assurance of clinical trial supplies
  • 2.5 Conclusions
  • Further reading
  • References
  • 3: Toxicity testing
  • 3.1 Introduction
  • 3.1.2 The drug development process
  • 3.1.3 Risk benefit
  • 3.2 Preclinical safety pharmocology
  • 3.2.1 Introduction
  • 3.2.2 Regulatory guidelines
  • 3.2.3 General considerations
  • 3.2.4 Experimental design
  • 3.2.4.1 Controls
  • 3.2.4.2 Route
  • 3.2.4.3 Dose levels in vivo
  • 3.2.4.4 Dose levels in vitro
  • 3.2.5 Safety pharmacology core battery
  • 3.2.5.1 Central nervous system

Ejemplares similares